W. Unicef, Towards Universal Access Scaling up priority HIV/AIDS interventions in the health sector, Progress Report, 2007.

P. Braitstein, M. Brinkhof, F. Dabis, M. Schechter, A. Boulle et al., Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries, Lancet, vol.367, pp.817-824, 2006.

J. Etard, I. Ndiaye, M. Thierry-mieg, N. Gueye, P. Gueye et al., Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study, AIDS, vol.20, issue.8, pp.1181-1190, 2006.
DOI : 10.1097/01.aids.0000226959.87471.01

C. Seyler, X. Anglaret, N. Dakoury-dogbo, E. Messou, S. Touré et al., Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Antivir Ther, vol.8, pp.385-393, 2003.

S. Lawn, L. Bekker, L. Myer, C. Orrell, and R. Wood, Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme, AIDS, vol.19, issue.17, pp.2050-2052, 2005.
DOI : 10.1097/01.aids.0000191232.16111.f9

S. Lawn, L. Myer, L. Bekker, and R. Wood, Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control, AIDS, vol.20, issue.12, pp.1605-1617, 2006.
DOI : 10.1097/01.aids.0000238406.93249.cd

C. Danel, R. Moh, A. Minga, A. Anzian, O. Ba-gomis et al., CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial, The Lancet, vol.367, issue.9527, pp.1981-1989, 2006.
DOI : 10.1016/S0140-6736(06)68887-9

C. Danel, R. Moh, A. Anzian, Y. Abo, H. Chenal et al., Tolerance and Acceptability of an Efavirenz-Based Regimen in 740 Adults (Predominantly Women) in West Africa, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.42, issue.1, pp.29-35, 2006.
DOI : 10.1097/01.qai.0000219777.04927.50

R. Moh, C. Danel, S. Sorho, D. Sauvageot, A. Anzian et al., Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d'Ivoire, Antivir Ther, vol.10, pp.615-639, 2005.

F. Rouet, D. Ekouevi, M. Chaix, M. Burgard, A. Inwoley et al., Transfer and Evaluation of an Automated, Low-Cost Real-Time Reverse Transcription-PCR Test for Diagnosis and Monitoring of Human Immunodeficiency Virus Type 1 Infection in a West African Resource-Limited Setting, Journal of Clinical Microbiology, vol.43, issue.6, pp.2709-2717, 2005.
DOI : 10.1128/JCM.43.6.2709-2717.2005

X. Anglaret, E. Messou, T. Ouassa, S. Toure, N. Dakoury-dogbo et al., Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, C??te d'Ivoire, AIDS, vol.17, issue.4, pp.575-584, 2003.
DOI : 10.1097/00002030-200303070-00013

C. Seyler, S. Toure, E. Messou, D. Bonard, D. Gabillard et al., Risk Factors for Active Tuberculosis after Antiretroviral Treatment Initiation in Abidjan, American Journal of Respiratory and Critical Care Medicine, vol.172, issue.1, pp.123-127, 2005.
DOI : 10.1164/rccm.200410-1342OC

L. Ferradini, A. Jeannin, L. Pinoges, J. Izopet, D. Odhiambo et al., Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment, The Lancet, vol.367, issue.9519, pp.1335-1377, 2006.
DOI : 10.1016/S0140-6736(06)68580-2

J. Stringer, I. Zulu, J. Levy, E. Stringer, A. Mwango et al., Rapid Scale-up of Antiretroviral Therapy at Primary Care Sites in Zambia, JAMA, vol.296, issue.7, pp.782-93, 2006.
DOI : 10.1001/jama.296.7.782

C. Laurent, N. Gueye, N. Ndour, C. Gueye, P. Diouf et al., Long-Term Benefits of Highly Active Antiretroviral Therapy in Senegalese HIV-1-Infected Adults, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.38, issue.1, pp.14-21, 2005.
DOI : 10.1097/00126334-200501010-00003

R. Zachariah, M. Fitzgerald, M. Massaquoi, O. Pasulani, L. Arnould et al., Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi, AIDS, vol.20, issue.18, pp.2355-60, 2006.
DOI : 10.1097/QAD.0b013e32801086b0

A. Calmy, L. Pinoges, E. Szumilin, Z. R. Ford, N. Ferradini et al., Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort, AIDS, vol.20, issue.8, pp.1163-1172, 2006.
DOI : 10.1097/01.aids.0000226957.79847.d6

P. Weidle, N. Wamai, P. Solberg, C. Liechty, S. Sendagala et al., Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda, The Lancet, vol.368, issue.9547, pp.1587-94, 2006.
DOI : 10.1016/S0140-6736(06)69118-6

C. Wester, S. Kim, H. Bussmann, A. Avalos, N. Ndwapi et al., Initial Response to Highly Active Antiretroviral Therapy in HIV-1C-Infected Adults in a Public Sector Treatment Program in Botswana, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.40, issue.3, pp.336-379, 2005.
DOI : 10.1097/01.qai.0000159668.80207.5b

D. Coetzee, K. Hildebrand, A. Boulle, G. Maartens, F. Louis et al., Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa, AIDS, vol.18, issue.6, pp.887-95, 2004.
DOI : 10.1097/00002030-200404090-00006

M. Badri, S. Lawn, and R. Wood, Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study, The Lancet, vol.368, issue.9543, pp.1254-1263, 2006.
DOI : 10.1016/S0140-6736(06)69117-4

W. Who, Expert Consultation on Cotrimoxazole Prophylaxis in HIV Infection. WHO technical report series. Reference number: WHO/HIV, 2006.

J. Mermin, J. Lule, J. Ekwaru, S. Malamba, R. Downing et al., Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda, The Lancet, vol.364, issue.9443, pp.1428-1462, 2004.
DOI : 10.1016/S0140-6736(04)17225-5

X. Anglaret, G. Chêne, A. Attia, S. Toure, S. Lafont et al., Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, C??te d'Ivoire: a randomised trial, The Lancet, vol.353, issue.9163, pp.1463-1471, 1999.
DOI : 10.1016/S0140-6736(98)07399-1

S. Lawn, L. Myer, G. Harling, C. Orrell, L. Bekker et al., Determinants of Mortality and Nondeath Losses from an Antiretroviral Treatment Service in South Africa: Implications for Program Evaluation, Clinical Infectious Diseases, vol.43, issue.6, pp.770-776, 2006.
DOI : 10.1086/507095

K. Anastos, Y. Barron, M. Cohen, R. Greenblatt, H. Minkoff et al., The Prognostic Importance of Changes in CD4^+Cell Count and HIV-1 RNA Level in Women after Initiating Highly Active Antiretroviral Therapy, Annals of Internal Medicine, vol.140, issue.4, pp.256-64, 2004.
DOI : 10.7326/0003-4819-140-4-200402170-00007

S. Lawn, M. Badri, and R. Wood, Risk Factors for Tuberculosis among HIV-infected Patients Receiving Antiretroviral Treatment, American Journal of Respiratory and Critical Care Medicine, vol.172, issue.10, pp.1348-1357, 1348.
DOI : 10.1164/ajrccm.172.10.1348

A. Harries, N. Hargreaves, J. Kwanjana, and F. Salaniponi, Relapse and recurrent tuberculosis in the context of a National Tuberculosis Control Programme, Transactions of the Royal Society of Tropical Medicine and Hygiene, vol.94, issue.3, pp.247-256, 2000.
DOI : 10.1016/S0035-9203(00)90306-7

V. Balasubramanian, K. Oommen, and R. Samuel, DOT or not? Direct observation of antituberculosis treatment and patient outcomes, Int J Tuberc Lung Dis, vol.4, pp.409-422, 2000.

T. Frieden, Lack of Directly Observed Treatment Affects Tuberculosis Relapse Rates, American Journal of Respiratory and Critical Care Medicine, vol.173, issue.3, pp.359-359, 2006.
DOI : 10.1164/ajrccm.173.3.359